Table 2.

Characteristics of the included studies for prognosis and clinicopathologic features

Study	Locale	Patient size	TNM stage (I/II/III/IV)	Sample type	CircRNA signature	Expression status	Survival indicator	Follow-up time	HR and 95%CI extraction	P-value (survival)	NOS scores
Cai et al[10], 2018	China	78	Unclear	Tissue	hsa_circ_0103809	Increased	OS	Unclear	Indirectly	0.001	6
Zhong et al[30], 2018	China	47	7, 15, 16, 9	Tissue	circC3P1	Decreased	OS	Unclear	Indirectly	0.030	6
Li et al[18], 2018	China	51	I–II: 24, III–IV: 27	Tissue	circRNA101368	Increased	OS	Unclear	Directly	0.001, 0.033	7
Weng et al[22], 2018	China	120	I–III: 60, 14, 46	Tissue	hsa_circ_0064428	Increased	OS	Unclear	Indirectly	0.033	7
Chen et al[11], 2018	China	78	Unclear	Tissue	hsa_circ_0128298	Increased	OS	Median: 37 months	Directly	0.009, 0.014	8
Gong et al[14], 2018	China	64	12, 22, 17, 13	Tissue	circ-ZEB1.33	Increased	OS	Unclear	Indirectly	0.015, 0.019	7
Yu et al[26], 2018	China	208	I: 62, II–III: 101	Tissue	cSMARCA5	Decreased	OS	Unclear	Directly	0.001, 0.021	7
Huang et al[17], 2017	China	80	I–II: 43, III–IV: 37	Tissue	hsa_circRNA_100338	Increased	OS	5 years	Indirectly	<0.01	8
Han et al[16], 2017	China	116	Unclear	Tissue	circMTO1	Decreased	OS	Unclear	Indirectly	0.0023	7
Guo et al[15], 2017	China	1800	Unclear	Tissue	circ-ITCH	Decreased	OS	Unclear	Directly	<0.001	6
Zhang et al[27], 2018	China	77	I–II: 34, III–IV: 43	Tissue	hsa_circ_0001649	Decreased	OS	Unclear	Directly	0.015, 0.011	6
Xu et al[23], 2018	China	76	I–II: 23, III–IV: 53	Tissue	hsa_circ_0001649	Decreased	/	/	/	/	/
Zhang et al[28], 2018	China	86	Early: 38, Late: 48	Tissue	circsMaD2	Decreased	/	/	/	/	/

circRNA: Circular RNA; OS: Overall survival; HR: Hazard ratio; NOS: Newcastle-Ottawa Scale; TNM: Tumor-node-metastasis.